# Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

> **NCT03551249** · NA · COMPLETED · sponsor: **InSightec** · enrollment: 20 (actual)

## Conditions studied

- Glioma
- Glioblastoma

## Interventions

- **DEVICE:** Focused ultrasound (FUS)

## Key facts

- **NCT ID:** NCT03551249
- **Lead sponsor:** InSightec
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03551249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03551249, "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03551249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*